On October 13, Shanghai Stock Exchange and China Securities Index Co., Ltd. officially announced the release arrangement of the SSE STAR Growth Index (referred to as STAR Growth). As one of two selected enterprises in Sichuan, OLYMVAX was successfully selected to be included in the list of sample enterprises to be released. This is another important index for OLYMVAX after being listed in the SSE STAR Biology and Medicine Index in April this year, indicating that the innovation and growth potential of OLYMVAX have been recognized by the capital market.

Figure 1

Figure 2    

As for STAR Growth Index, there will be 50 securities of listed companies with top comprehensive growing performance selected as index samples on the basis of the growth rate of operating revenue and net profit in the short and medium term, so as to highlight the growth ability of constituent stocks, which will be complementary to the positioning of STAR 50 Index, reflecting the overall performance of securities of listed companies with high growth characteristics on the Science and Technology Innovation Board.

OLYMVAX has always been committed to scientific research and development, as well as the transformation of achievements. At present, it has obtained more than 100 patents and 3 vaccine products on the market, forming a product pipeline of “multi-product reserve, orderly stepping and key breakthrough”. In the future, OLYMVAX will continue to uphold its sacred mission of providing safer, high-quality, and efficient vaccine products for human health, make more innovations and improvements by means of cutting-edge technologies and management in the world, and strive to develop OLYMVAX into an internationally renowned and domestically leading vaccine supplier.